Kewaunee Scientific KEQU
- Market cap
- $94.9M
- PE
- 11.9×
- 10y median 13.7×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.3×
- EV/EBIT
- 7.2×
- Revenue, 12 months
- $277.2M
- +5% on a year ago
- Net margin
- 3.0%
- Free cash flow yield
- 11.5%
Kewaunee Scientific trades at 11.9× trailing earnings, near its ten-year median. Revenue was $277.2M over the last twelve months, up 5% on a year earlier with a 3% net margin.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $50.4M−8% | $46.8M−23% | $56.7M+5% | $48.4M−3% | $47.8M−5% | $67.2M+44% | $77.1M+36% | $71.1M+47% | $70.1M+47% | $69.4M+3% | $71.4M−8% | $66.3M−7% | |
| Cost of revenue | $37M−19% | $34.7M−31% | $42.1M−4% | $35.9M−5% | $33.8M−9% | $48.8M+40% | $53.1M+26% | $50.2M+40% | $50.4M+49% | $50.9M+4% | $50.2M−6% | $46.7M−7% |
| Gross profit | $13.5M+55% | $12M+16% | $14.6M+41% | $12.5M+5% | $14M+4% | $18.4M+53% | $24M+64% | $20.9M+68% | $19.7M+41% | $18.5M+1% | $21.2M−12% | $19.6M−6% |
| $5.1M+577% | $3.8M+65% | $5.6M+106% | $2.6M−32% | $4.4M−13% | $2.3M−41% | $8.5M+53% | $4.8M+87% | $4.1M−7% | $2.6M+15% | $5.2M−39% | $3.2M−34% | |
| Interest expense | $372K+1% | $411K−6% | $586K+8% | $472K+10% | $442K+19% | $1.1M+177% | $1.2M+99% | $1.1M+124% | $1.1M+140% | $1.1M−2% | $631K−46% | $626K−41% |
| Pre-tax income | $4.8M+963% | $3.5M+71% | $1.3M−42% | $2.4M−29% | $3.9M−19% | $1.3M−64% | $7.1M+431% | $3.9M+61% | $3.5M−12% | $1.6M+26% | $4.8M−34% | $2.6M−35% |
| $2M+254% | $982K+2% | −$9.8M | $192K−79% | $916K−55% | −$108K | $2.2M | $761K+296% | $915K−0% | $528K | $1.1M−52% | $717K−6% | |
| Net income | $2.7M | $2.5M+249% | $11M+997% | $2.2M−11% | $3M+10% | $1.4M−46% | $4.8M−56% | $3.1M+41% | $2.4M−19% | $692K−49% | $3.4M−30% | $1.7M−45% |
| $0.93 | $0.85+240% | $3.71+960% | $0.74−14% | $1.01+9% | $0.45−47% | $1.63−56% | $1.04+41% | $0.82−19% | $0.23−49% | $1.13−31% | $0.58−44% | |
| 2.9M+4% | 3M+2% | 3M+2% | 3M+3% | 3M+2% | 3M+1% | 3M+0% | 3M−0% | 3M+1% | 3M−0% | 3M+1% | 2.9M−1% |
EPS, diluted: 6 periods, Q4 FY11 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY11 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12 and Q4 FY23: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. 4 periods, Q4 FY19 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Kewaunee Scientific's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| Peer median | $277.6M | 21.9× | 20.9× | 1.6× | +5% | 7.1% |
More on Kewaunee Scientific
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 45Medical instruments and supplies stocks with the highest free cash flow yield
- #8of 116Medical instruments and supplies stocks with the lowest price to sales ratio
- #3of 35Medical instruments and supplies stocks with the lowest PE ratio
- #4of 46Medical instruments and supplies stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .